Cytokinetics (CYTK) Common Equity (2016 - 2025)
Historic Common Equity for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to -$13.9 million.
- Cytokinetics' Common Equity rose 9682.98% to -$13.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$13.9 million, marking a year-over-year increase of 9682.98%. This contributed to the annual value of -$386.3 million for FY2023, which is 25803.8% down from last year.
- As of Q3 2024, Cytokinetics' Common Equity stood at -$13.9 million, which was up 9682.98% from $108.6 million recorded in Q2 2024.
- Cytokinetics' 5-year Common Equity high stood at $249.0 million for Q3 2021, and its period low was -$438.8 million during Q3 2023.
- In the last 5 years, Cytokinetics' Common Equity had a median value of -$13.9 million in 2024 and averaged -$45.7 million.
- Its Common Equity has fluctuated over the past 5 years, first surged by 113669.2% in 2020, then crashed by 264645.43% in 2023.
- Cytokinetics' Common Equity (Quarter) stood at $113.4 million in 2020, then skyrocketed by 115.08% to $243.9 million in 2021, then plummeted by 144.25% to -$107.9 million in 2022, then crashed by 258.04% to -$386.3 million in 2023, then skyrocketed by 96.4% to -$13.9 million in 2024.
- Its Common Equity stands at -$13.9 million for Q3 2024, versus $108.6 million for Q2 2024 and -$396.2 million for Q1 2024.